The Asia Pacific Newborn Screening Market would witness market growth of 7.2% CAGR during the forecast period (2022-2028).
Newborn screening is a public health initiative aimed at identifying infants with treatable illnesses before they manifest clinically or cause irreparable damage. The first disorder to be targeted for the newborn screening was phenylketonuria (PKU), which was adopted in a small number of hospitals before fast spreading throughout the United States and the rest of the country. During the first two years after newborn screening for PKU was achieved, through investigation other disorders that infants could be diagnosed with and treated (39 infants were diagnosed and treated without false negatives); a gradual development bacterial inhibition assay was used to identify classic galactosemia and maple syrup urinary illness.
Since the emergence of PKU screening in the 1960s, newborn screening has become more widespread, albeit it varies widely by country. In 2011, the US screened for 54 disorders, Germany for 12, the UK for two, while France and Hong Kong only screened for one. The conditions included in newborn screening vary greatly across the world, depending on regulatory obligations for screening programs, the prevalence of certain diseases in inhabitants, government pressure, and the access to resources both for testing and obey of recognized patients.
India has an estimated 26 million babies per year. According to the 2011 Census, 13% of the population is between the ages of 0 and 6. Child health programs at the National Health Mission (NHM) focus on promoting child survival as well as addressing factors associated with infant and under-five mortality rates. It is impossible to handle the child's survival in isolation since it is closely tied to the mother's health, which is further influenced by her development as a teenager. India has made headway in reducing newborn mortality, with its share of the newborn mortality load falling from one-third in 1990 to less than a quarter of all newborn fatalities now. In India, there are roughly one million fewer neonatal fatalities and 10,000 fewer maternal deaths per month in 2017 than in 2000. This is due to an increase in the number of women giving birth in hospitals.
The China market dominated the Asia Pacific Newborn Screening Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $128.8 Million by 2028. The Japan market is poised to grow at a CAGR of 6.5% during (2022 - 2028). Additionally, The India market would witness a CAGR of 7.8% during (2022 - 2028).
Based on Product Type, the market is segmented into Consumables and Instrument. Based on Test Type, the market is segmented into Blood Test, Hearing Screening Test, and Heart screening. Based on End User, the market is segmented into Hospitals and Clinical Laboratories. Based on Technology, the market is segmented into Tandem Mass Spectrometry (TMS), Molecular Assays, Immunoassays & Enzymatic Assays, Hearing Screen Technology, Pulse Oximetry Screening Technology, Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Newborn Screening Market is Projected to reach USD 1.6 Billion by 2028, at a CAGR of 6.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include General Electric (GE) Co. (GE Healthcare), F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Natus Medical Incorporated, Masimo Corporation, Waters Corporation, PerkinElmer, Inc., AB Sciex LLC (Danaher Corporation), Medtronic PLC (Covidien plc), Trivitron Healthcare Pvt. Ltd.
By Product Type
By Test Type
By End User
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
